Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 124Multiple Myeloma 83Precursor Cell Lymphoblastic Leukemia-Lymphoma 74Lymphoma 73Lymphoma, Non-Hodgkin 65Leukemia 65Myelodysplastic Syndromes 56Hodgkin Disease 53Lymphoma, Large B-Cell, Diffuse 37Lymphoma, Mantle-Cell 33Breast Neoplasms 31Leukemia, Lymphocytic, Chronic, B-Cell 30Burkitt Lymphoma 30Neuroblastoma 29Lymphoma, Follicular 26Leukemia, Myelogenous, Chronic, BCR-ABL Positive 26Recurrence 24Sarcoma 18Neoplasms, Plasma Cell 18Hematologic Neoplasms 18Central Nervous System Neoplasms 18Lymphoma, B-Cell, Marginal Zone 17Leukemia, Biphenotypic, Acute 16Myeloproliferative Disorders 15Lymphoma, Large-Cell, Immunoblastic 15Congenital Abnormalities 15Brain Neoplasms 14Leukemia, Myelomonocytic, Chronic 13Anemia, Refractory, with Excess of Blasts 13Medulloblastoma 12

Interventions

Cyclophosphamide 9Pemetrexed 6pembrolizumab 5fludarabine 5Gemcitabine 5Cisplatin 5Carboplatin 5ponatinib 4atezolizumab 4Rituximab 4Dexamethasone 4Bevacizumab 4130-nm albumin-bound paclitaxel 4Sunitinib 3Melphalan 3Doxorubicin 3Bortezomib 3tetulomab tetraxetan lu-177 2pralsetinib 2pomalidomide 2osimertinib 2napabucasin 2isatuximab 2fludarabine phosphate 2ficlatuzumab 2entrectinib 2entinostat 2durvalumab 2cobimetinib 2capmatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neoplasms by Histologic Type × Granulocyte Colony-Stimulating Factor × Clear all
NCT06001788 2026-04-14

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

Kura Oncology, Inc.

Phase 1 Recruiting
171 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Neoplasms by Histologic Type, Leukemia, Myeloid, Acute, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡